Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-cirrhotic treatment-naïve participants~* FIB-4 \< 3.25~* albumin \> 3.5~* total bilirubin \< 1.2 mg/dl~* international normalized ratio (INR) \< 1.2~* platelet count \> 150,000 mm3.~* experienced participants who had previously failed treatment with peg-IFN-α-/RBV, SOF/peg-IFN-α +RBV, or SOF/SMV~* Naïve cirrhotic participants were confirmed by ultrasonographic features of cirrhosis~Exclusion Criteria:~* liver disease of non-HCV etiology~* hepatitis B or human immune-deficiency virus (HIV) infection~* poorly controlled diabetic (HbA1C \> 9) participants~* hepatocellular carcinoma~* a history of extra-hepatic malignancy within 5 years prior to the study~* pregnant or breast feeding~* renal disease; serum creatinine \> 2.5 mg/dl or eGFR \< 30 ml/min~* evidence of hepatic decompensation; INR \> 1.7, serum albumin \< 2.8 g/dl, total bilirubin \> 3 mg/dl~* blood picture abnormalities such as anemia (hemoglobin concentration of 10 g/dl or less) and thrombocytopenia (platelet count \< 50,000 cells/mm3)~* major severe illnesses such as congestive heart failure and respiratory failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF/DCV (Type: ACTIVE_COMPARATOR): Easy to treat arm: Participants were treated with a dual therapy (SOF and DCV) for 12 weeks.~This arm included non-cirrhotic treatment-naïve patients
- SOF/DCV/RBV + Cirrhosis (Type: ACTIVE_COMPARATOR): This difficult-to-treat arm included 111 cirrhotic participants who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.
- SOF/DCV/RBV + Non-Cirrhosis (Type: ACTIVE_COMPARATOR): This difficult-to-treat arm included treatment-experienced non-cirrhotic participants (77 participants) who were treated with a triple therapy (SOF, DCV, and RBV) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).